GI Colorectal / Rectal Cancer (CRC)

**Localized**
- Colon
- Rectal

**Adjuvant**
- Colon
- Anal (Squamous Cell)

**Neoadjuvant / Adjuvant**
- Rectal

**Non-Intervention CRC**

**Metastatic CRC**
- **1st Line**
- **2nd Line**
- **3rd Line**
- Beyond 3rd Line HER2+

**Metastatic Anal**

**IRB# 21658**
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

**IRB# 19576**
Phase 1B Study to Assess the Safety of Neoadjuvant TAS-102 (Lonsurf) with Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer

**IRB# 20980**
Immunotherapy during neoadjuvant therapy for rectal cancer, a phase II randomized multi-center trial with and without APX005M, an anti-CD40 agonist

**IRB# 22465**
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

**IRB# 22189**
A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

**IRB# 20681**
An Implementation Science Interventional study of increasing CRC screening using Evidence-based Interventions (outreach and patient navigation) in Rural settings

**IRB# 21972**
A Phase 3 Study to Evaluate the Efficacy and Safety of Olaparib Alone Or In Combination With Bevacizumab Compared To Bevacizumab With 5-Fu In Participants With Unresectable Or Metastatic Colorectal Cancer Who Have Not Progressed Following First-Line Induction Of FOLFOX With Bevacizumab

**IRB# 20747**
A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

**CROSS-DISEASE TRIALS:**
- **IRB# TBD**
  EAY131 (MATCH)

**NO TRIALS CURRENTLY AVAILABLE**

---

http://www.ohsu.edu/research/rda/so/knight.php

---

**6/3/2021**